Vizsgálati helyszín
Memorial Sloan Kettering Cancer Center Mskcc
New York, New York 10065-6800, Egyesült ÁllamokMég nincs intézményhez kötve
- 13futó vizsgálat
- 4lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 17 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 1/2. fázis8 vizsgálat
- 2. fázis4 vizsgálat
- 3. fázis4 vizsgálat
- 1. fázis1 vizsgálat
- Állapot
- Toboroz11 vizsgálat
- Lezárult3 vizsgálat
- Fut, nem toboroz2 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- BeOne Medicines8 vizsgálat
- BeiGene1 vizsgálat
- BioNTech SE1 vizsgálat
- Caribou Biosciences, Inc.1 vizsgálat
- Daiichi Sankyo1 vizsgálat
- és még 5
Futó vizsgálatok
Toboroz
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
NCT07262619· 1/2. fázis· Eikon Therapeutics· Forrás
Contact: Ana C Mamede, PharmD
Toboroz
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· 3. fázis· BeOne Medicines· Forrás
Contact: Study Director
Toboroz
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· 3. fázis· BeOne Medicines· Forrás
Contact: Study Director
Toboroz
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548· 1/2. fázis· BioNTech SE· Forrás
Toboroz
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671· 3. fázis· BeOne Medicines· Forrás
Contact: Study Director
Toboroz
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996· 3. fázis· BeOne Medicines· Forrás
Contact: Study Director
Toboroz
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
NCT06785636· 1/2. fázis· Pathos AI, Inc.· Forrás
Contact: Nicholas Mai
Toboroz
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941· 1/2. fázis· BeOne Medicines· Forrás
Contact: Study Director
Fut, nem toboroz
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037· 2. fázis· BeOne Medicines· Forrás
Fut, nem toboroz
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
NCT05544552· 1/2. fázis· Tyra Biosciences, Inc· Forrás
Toboroz
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
NCT04959903· 1/2. fázis· Smart Immune SAS· Forrás
Contact: Jaap-Jan BOELENS, MD, PhD (principal investigator)
Toboroz
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
NCT04973605· 1/2. fázis· BeOne Medicines· Forrás
Contact: BeOne Medicines
Toboroz
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716· 1/2. fázis· BeOne Medicines· Forrás
Contact: BeOne Medicines
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek